Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs) have become an important part of the treatment of multiple cancers, especially for advanced melanoma and non-small cell lung cancer. Some tumors are capable of escaping immunosurveillance by stimulating checkpoints on T-cells. ICIs prevent activation of these checkpoints and thereby stimulate the immune system and indirectly the anti-tumor response. However, the use of ICIs is associated with various adverse events. Ocular side effects are rare but may have a major impact on the quality of life of the patient.

Methods

A comprehensive literature search of the medical databases Web of Science, Embase and PubMed was performed. Articles that provided a comprehensive description of a case report containing 1) cancer patient(s) trea

SUBMITTER: Martens A 

PROVIDER: S-EPMC9947214 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature